Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289780 · ClinicalTrials.gov registry record
Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects
A clinical trial of Non-Small Cell Lung Cancer, sponsored by Biodesix.
- Active
- Registry status
- 5,006
- Enrollment target
- 20
- Study locations
NCT03289780: Active study of Non-Small Cell Lung Cancer, sponsored by Biodesix.
NCT03289780 is a study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Biodesix. The registered enrollment target is 5,006 participants, above the 641-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (681% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03289780, a study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Biodesix.
- ACTIVE NOT RECRUITING
- Registry status
- 5,006 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.
Primary Outcome
Physician Treatment patterns Description: To describe physician treatment patterns pre and post-veriStrat testing. Describe the impact of the VeriStrat test results on treatment decisions, including but not limited to: percentage change in treatment decision, differences in chosen treatments between patients classified as VeriStrat good and those classified as VeriStrat Poor. Change in percentage of patients receiving systemic therapy or supportive therapies only.
Conditions Studied
Study Locations (20)
Georgia
- South Eastern Regional Medical Center - Newnan
- Summit Cancer Care - Savannah
- South Georgia Medical Center - Valdosta
Alabama
- Oncology Specialties, PC; Clearview Cancer Institute - Huntsville
- Lewis & Faye Manderson Cancer Center at DCH Regional Medical Center - Tuscaloosa
Arkansas
- Highlands Oncology Group - Fayetteville
- St. Bernards Cancer Center Hematology / Oncology - Jonesboro
Florida
- Boca Raton Regional Hospital -Lynn Cancer Institute - Boca Raton
- Lake City Cancer Care, LLC - Lake City
Illinois
- Edward-Elmhurst Healthcare - Naperville
- Illinois Cancer Care - Peoria
Indiana
- Franciscan St. Francis Health - Indianapolis
- Franciscan Health Woodland Cancer Center - Michigan City
Louisiana
- Ponchartrain Cancer Center - Covington
- Christus Health - Shreveport
Missouri
- Central Care Cancer Center - Bolivar
- Phelps County Regional Medical Center - Rolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,006 participants |
| Start Date | 2016-04-04 |
| Est. Completion | 2025-12 |
What the registry record for NCT03289780 still lists
NCT03289780 is an observational study that tracks outcomes without assigning an intervention. Its 5,006 participants enrollment target places it among the larger protocols in the corpus, above the 641-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (681% higher).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03289780 names 20 study sites across 11 states, led by Georgia, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03289780 about?
NCT03289780 is a clinical study titled "Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects". The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to be...
What is the current status of trial NCT03289780?
This trial is currently active not recruiting. The enrollment target is 5,006 participants. The study started on 2016-04-04. Estimated completion is 2025-12.
What conditions does trial NCT03289780 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
Who is sponsoring clinical trial NCT03289780?
This trial is sponsored by Biodesix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03289780 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03289780's enrollment target sits among peer trials
5,006 4th of 454 higher than 451 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743362 · 5,010 participants
A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI